Stocks
Funds
Screener
Sectors
Watchlists
ALPN

ALPN - Alpine Immune Sciences Inc Stock Price, Fair Value and News

$8.80-0.10 (-1.12%)
Market Closed

48/100

ALPN

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

48/100

ALPN

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

ALPN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ALPN Price Action

Last 7 days

-1.1%

Last 30 days

-0.6%

Last 90 days

2.3%

Trailing 12 Months

17.8%

ALPN RSI Chart

ALPN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ALPN Valuation

ALPN Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

ALPN Fundamentals

ALPN Revenue

ALPN Earnings

ALPN Profitability

ALPN Investor Care

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202456.5M000
202325.8M29.1M30.8M58.9M
202233.9M32.0M31.8M30.1M
202111.4M18.0M24.6M23.4M
20202.8M3.0M4.6M9.3M
201901.1M1.4M1.7M
20181.3M908.0K1.1M705.0K
20172.6M2.3M2.0M1.7M
2016001.7M3.0M
2015000492.0K
ALPN
Alpine Immune Sciences, Inc., a clinical-stage company, focuses on immune therapeutics. The company has strategic collaborations immunotherapies via protein engineering technologies with biopharmaceutical companies and has a pipeline of clinical and preclinical candidates in development. Its pipeline includes Povetacicept (ALPN-303), which is in a phase 1b, open-label study of povetacicept in autoimmune cytopenias, including immune thrombocytopenia, warm autoimmune hemolytic anemia, and cold agglutinin disease; and in phase 1b/2a, open-label study of povetacicept in autoimmune glomerulonephritis, including IgA nephropathy, lupus nephritis, and primary membranous nephropathy. The company is also developing Acazicolcept (ALPN-101), which is in a phase 2 study of acazicolcept in patients with Systemic Lupus Erythematosus. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.
 CEO
 WEBSITEalpineimmunesciences.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES126

Alpine Immune Sciences Inc Frequently Asked Questions


ALPN is the stock ticker symbol of Alpine Immune Sciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

In the past 10 years, Alpine Immune Sciences Inc has provided -0.058 (multiply by 100 for percentage) rate of return.